Prostate specific antigen(PSA) is widely used as a marker for screening and monitoring prostate cancer. However, there are several assay methods, which often give different PSA values for the same patient sample. A possible cause of these discrepancies might be the varied immunoreactivity with free-PSA and complex-PSA among methods.
This study revealed that pre-treatment of samples with anti-free-PSA monoclonal antibodies improved polyclonal antibodies-based non equimolar PSA assay to equimolar assay.
This might be achieved by that the monoclonal antibodies bind to free-PSA and then change its reactivities with polyclonal antibodies to those similar to complex-PSA.
[Rinsho Byori 50 : 202`206, 2002]
*1Japan Clinical Laboratories, Inc. Kuze-gun, Kyoto-pref. 613-0046
yKey Wordszprostate specific antigenFPSA(O§BΑΩR΄)Cfree-PSA(V£^ PSA)Ccomplex-PSA(^ PSA)Cenzyme-linked immunosorbent assayFELISA(yfΖuͺθ@)Cequimolar assay(½n)
σt2001N829ϊEσ2001N1115ϊ
*1`3Mϊ{γwΥ°Έ€wp€Ϋ(§613-0046 s{v’SvδR¬ε΄Σ16-10)
E-mail :e.kimura@lnm.jcl.co.jp